Mazdutide Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is Mazdutide?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Obesity, type 2 diabetes, metabolic syndrome, non-alcoholic fatty liver disease, hyperuricemia
• Molecular Origin: Synthetic analog of oxyntomodulin (OXM), a naturally occurring gut-derived peptide
• Alternative Codes: IBI362, LY3305677
• Half-Life: Approximately 8 days, supporting once-weekly subcutaneous dosing
• Key Mechanisms: Dual GLP-1 receptor and glucagon receptor agonism; appetite suppression, thermogenesis, hepatic fat oxidation
• Developer: Originally (LY3305677); licensed to Innovent Biologics for China development; retains ex-China rights
• Clinical Trial Status: Seven Phase 3 trials completed or ongoing as of 2024; five primary endpoints met; data presented at EASD 2024
• Peak Weight Reduction Observed: Up to 20.1% body weight reduction at 52 weeks (GLORY-2 Phase 3 trial)
• Regulatory Classification: Investigational compound; not approved for human therapeutic use in any jurisdiction as of available data

What is Mazdutide?

Mazdutide is a synthetic peptide derived from oxyntomodulin, a 37-amino acid peptide naturally produced by L-cells in the small intestine in response to nutrient intake. Oxyntomodulin itself acts on both the GLP-1 receptor and the glucagon receptor, producing appetite suppression and increased energy expenditure simultaneously. Scientists recognized this dual-receptor activity as a potential therapeutic advantage and developed mazdutide as a more potent, longer-acting analog optimized for research and clinical applications.

The compound was initially developed by under the research code LY3305677. Innovent Biologics licensed the compound for development and commercialization in China, assigning it the code IBI362 and the generic name mazdutide. retains rights outside China. This bifurcated development pathway means the compound has advanced through an extensive clinical program primarily in Chinese populations while international development continues separately.

What distinguishes mazdutide from the now-dominant class of GLP-1 receptor agonists is its glucagon receptor component. Single-target GLP-1 agents like GLP1-S and dulaglutide achieve meaningful weight loss and glycemic improvement through insulin stimulation and appetite suppression. Mazdutide adds glucagon receptor activation to this profile, which increases hepatic fat oxidation, elevates thermogenesis, and promotes lipolysis. The theoretical concern with glucagon receptor activation is hyperglycemia, but mazdutide’s GLP-1 receptor activity counterbalances this, allowing metabolic benefits from glucagon signaling without net glucose elevation.

A fatty acid chain modification extends mazdutide’s half-life to approximately 8 days. This modification allows once-weekly subcutaneous dosing, a practical dosing interval that matches other established GLP-1 class agents. The half-life extension results from increased albumin binding and reduced renal clearance caused by the fatty acid chain.

All mazdutide research to date involves human clinical trials conducted in controlled research settings or animal model studies. This compound is classified as investigational and is not approved for any therapeutic use.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

Mazdutide’s backbone sequence derives from oxyntomodulin, which shares its N-terminal 29 amino acids with glucagon. This structural similarity explains the dual receptor binding capacity: the glucagon-homologous segment activates the glucagon receptor while modifications elsewhere confer GLP-1 receptor affinity.

The fatty acid chain conjugation is the primary structural modification distinguishing mazdutide from native oxyntomodulin. This lipid attachment enables albumin binding in circulation, dramatically slowing renal clearance and extending the period of receptor activity. The result is pharmacologically meaningful receptor engagement across a 7-day dosing interval rather than the minutes-to-hours activity of native oxyntomodulin.

Receptor binding potency differs between the two targets. Mazdutide demonstrates relatively higher potency at the glucagon receptor compared to the GLP-1 receptor, though both receptors are meaningfully activated at clinical doses. This receptor potency balance contributes to the compound’s metabolic profile, particularly the pronounced effects on hepatic fat oxidation and thermogenesis that distinguish it from GLP-1-selective agents.

Mechanisms of Action Being Investigated

Mazdutide activates two distinct G-protein coupled receptors simultaneously, producing parallel and complementary biological effects. Each receptor engagement initiates different downstream signaling cascades, and the combined output drives broader metabolic improvement than either receptor alone can achieve.

GLP-1 Receptor Activation and Glucose-Dependent Insulin Secretion

Mazdutide binds and activates the GLP-1 receptor on pancreatic beta cells, triggering glucose-dependent insulin secretion. The glucose-dependence is critical: insulin release occurs only when blood glucose is elevated, avoiding hypoglycemia at euglycemic states. This mechanism directly reduces postprandial glucose spikes and contributes to HbA1c reduction in diabetic research models [1].

GLP-1 receptor activation also occurs in the central nervous system, particularly the hypothalamus and brainstem. These brain regions regulate appetite and satiety signals. Mazdutide’s CNS GLP-1 receptor engagement reduces food intake by extending satiety and reducing appetite drive, contributing substantially to the body weight reductions observed in clinical trials [2].

GLP-1 Receptor Effects on Gastric Emptying and Peripheral Insulin Sensitivity

Beyond pancreatic insulin secretion, GLP-1 receptor activation slows gastric emptying. Delayed gastric transit reduces the rate of glucose absorption from meals, flattening postprandial glucose curves independently of insulin effects. Peripheral insulin sensitivity also improves through GLP-1R-mediated pathways in liver and muscle tissue, though the exact cellular mechanisms remain under investigation [3].

Glucagon Receptor Activation and Hepatic Fat Oxidation

The glucagon receptor component drives mazdutide’s most distinctive metabolic effects. Glucagon receptor activation in the liver increases fatty acid oxidation, the process by which hepatic cells burn fat for energy rather than storing it. This manifests as elevated beta-hydroxybutyrate in circulation, a direct biomarker of increased hepatic fat burning. Phase 1 trial data confirmed elevated beta-hydroxybutyrate following mazdutide treatment, validating this mechanism in human subjects [4].

Hepatic glucagon receptor signaling also reduces liver fat accumulation, making mazdutide relevant to non-alcoholic fatty liver disease research. Studies show reduced liver enzyme levels (ALT) and reduced hepatic fat content in subjects receiving mazdutide, consistent with this hepatic mechanism [5].

Glucagon Receptor Effects on Energy Expenditure and Thermogenesis

Glucagon receptor activation increases whole-body energy expenditure by stimulating brown adipose tissue thermogenesis and skeletal muscle metabolic rate. This effect adds an expenditure dimension to mazdutide’s weight loss mechanism that GLP-1-only agents lack. The combined reduction in caloric intake (via GLP-1R appetite suppression) and increase in caloric expenditure (via GCGR thermogenesis) produces greater weight reduction than either mechanism alone [6].

Lipolysis — the mobilization of stored fat from adipose tissue — also increases through glucagon receptor signaling. This provides additional substrate for hepatic fat oxidation and contributes to reductions in waist circumference observed across clinical trials.

Counterbalancing Hyperglycemia Risk

Native glucagon raises blood glucose by stimulating hepatic glycogenolysis and gluconeogenesis. Mazdutide’s glucagon receptor activity triggers these same pathways. However, concurrent GLP-1 receptor activation stimulates insulin secretion, which counteracts the glucagon-driven glucose increase. The net glycemic effect is neutral to beneficial, with clinical trials demonstrating HbA1c reductions rather than elevations even with active GCGR engagement [7].

Preclinical Neuroprotective Findings

Animal studies using male db/db mice — a standard type 2 diabetes model — compared mazdutide to the GLP-1-selective agent dulaglutide on cognitive and neurological endpoints. Mazdutide outperformed dulaglutide on measures of cognitive function, neuronal integrity, and markers of brain pathology. Transcriptomic, proteomic, and metabolomic analyses suggested mazdutide engagement of synaptic plasticity pathways and neuroprotective mechanisms not fully activated by GLP-1-only agents [8]. These findings are preclinical only; no human clinical data exists for mazdutide neuroprotective effects.

Major Areas of Research

Mazdutide research spans several metabolic and systemic conditions, with the most extensive data in obesity and type 2 diabetes. Human clinical trial data exists across multiple indication areas, an unusual distinction for a research peptide.

Obesity and Body Weight Reduction Research

Obesity research constitutes the largest body of mazdutide clinical data. Phase 1 through Phase 3 trials consistently demonstrate meaningful body weight reductions exceeding those of established GLP-1 agents in comparable populations.

Phase 1 dose escalation studies showed 11.7% body weight reduction at 12 weeks with the 9 mg dose compared to 1.8% with placebo [9]. Phase 2 trials extended this finding, with the 6 mg dose producing 11.3% weight reduction at 24 weeks and 50.8% of participants achieving at least 10% body weight loss [10]. The GLORY-2 Phase 3 trial achieved the most notable result: up to 20.1% body weight reduction at 52 weeks in obese adults without diabetes, accompanied by reductions in waist circumference, blood lipids, blood pressure, uric acid, liver enzymes, and hepatic fat content [11].

Key Research Highlights:

• 11.7% body weight reduction at 12 weeks in Phase 1 dose escalation (9 mg dose)
• 50.8% of Phase 2 participants achieved at least 10% weight loss at 24 weeks (6 mg dose)
• Up to 20.1% body weight reduction at 52 weeks in GLORY-2 Phase 3 trial
• Consistent cardiometabolic improvements accompanying weight loss across all trials

Type 2 Diabetes and Glycemic Control Research

Glycemic control research in type 2 diabetes establishes mazdutide’s potential in a distinct indication from obesity. Phase 2 studies in Chinese adults with type 2 diabetes showed HbA1c reductions of 1.41% to 1.67% at 20 weeks, dose-dependent and clinically meaningful [12].

The DREAMS-2 Phase 3 trial directly compared mazdutide 4 mg and 6 mg weekly against dulaglutide 1.5 mg weekly in Chinese adults with type 2 diabetes on oral antidiabetic agents. Mazdutide demonstrated superior HbA1c reduction (0.25 to 0.30 percentage points greater than dulaglutide), superior weight loss, and a greater proportion of participants achieving the composite endpoint of HbA1c below 7.0% plus at least 5% weight loss. Additional superiority over dulaglutide was observed for fasting glucose, postprandial glucose, waist circumference, blood pressure, lipids, uric acid, and liver enzymes [13].

Key Research Highlights:

• HbA1c reductions of 1.41-1.67% in Phase 2 diabetic population at 20 weeks
• Superior HbA1c reduction versus dulaglutide 1.5 mg in DREAMS-2 Phase 3 trial
• Superior weight loss versus dulaglutide in head-to-head comparison
• Favorable hypoglycemia profile when used as monotherapy or combination

Non-Alcoholic Fatty Liver Disease Research

Hepatic fat reduction is a direct consequence of mazdutide’s glucagon receptor activation of hepatic fatty acid oxidation. Multiple trials report reduced liver enzyme levels (ALT) and reduced hepatic fat content as secondary endpoints, establishing this as a consistent biological effect rather than an incidental finding [5].

GLORY-2 Phase 3 data specifically included hepatic fat content measurement at 52 weeks and demonstrated significant reduction. Elevated beta-hydroxybutyrate levels across trials confirm the underlying mechanism of increased hepatic fat burning rather than simply reduced dietary fat intake. These findings position mazdutide as relevant to NAFLD research independent of its weight loss effects [4,11].

Key Research Highlights:

• Consistent ALT reductions across Phase 2 and Phase 3 trials
• Reduced hepatic fat content confirmed in GLORY-2 at 52 weeks
• Elevated beta-hydroxybutyrate confirms hepatic fat oxidation as active mechanism
• Effects appear to exceed those of GLP-1-selective comparators in head-to-head data

Cardiovascular and Cardiometabolic Risk Research

Cardiometabolic risk factor improvement occurs alongside weight loss and glycemic improvement in mazdutide studies. Blood pressure reductions, lipid profile improvements, and waist circumference reductions are reported consistently across Phase 2 and Phase 3 trials in both diabetic and non-diabetic populations [10,13].

The DREAMS-2 comparison against dulaglutide showed mazdutide superiority on blood pressure, total cholesterol, LDL cholesterol, triglycerides, and uric acid — all established cardiovascular risk markers. Whether these cardiometabolic improvements translate to reduced cardiovascular events in long-term trials remains unstudied. No dedicated cardiovascular outcome trial has been published for mazdutide as of available data [13].

Key Research Highlights:

• Consistent blood pressure reduction across Phase 2 and Phase 3 trials
• Improved lipid profiles including LDL, triglycerides, and total cholesterol
• Uric acid reduction observed, relevant to gout risk and cardiometabolic health
• Superiority over dulaglutide on cardiometabolic markers in head-to-head Phase 3

Hyperuricemia Research

Uric acid reduction appears as a consistent secondary finding across mazdutide trials. The DREAMS-2 Phase 3 trial showed mazdutide superiority over dulaglutide on uric acid reduction. A separate adolescent case report included a 15-year-old with concurrent obesity, type 2 diabetes, and hyperuricemia who showed reduced uric acid levels following mazdutide treatment alongside improved HbA1c and BMI [14].

The mechanism for uric acid reduction is not fully characterized. Hypothesized pathways include reduced hepatic uric acid production secondary to improved metabolic function and increased renal uric acid excretion through weight-loss-associated mechanisms. This finding has prompted inclusion of hyperuricemia as an explicit research indication in mazdutide patent filings [14].

Key Research Highlights:

• Uric acid reduction consistently observed across multiple trial populations
• Mazdutide superior to dulaglutide on uric acid reduction in DREAMS-2
• Reduction observed in adolescent case report with concurrent hyperuricemia
• Mechanism incompletely characterized; under active investigation

Post-Bariatric Surgery Adjuvant Research

The SMART trial (NCT07135141) is a 96-week Phase 3 study investigating mazdutide as adjuvant therapy following sleeve gastrectomy in adults with severe obesity. This represents a distinct research application: rather than replacing bariatric surgery, the study tests whether mazdutide enhances or maintains weight loss outcomes achieved surgically. The trial uses a multicenter, randomized, double-blind, placebo-controlled superiority design and was actively recruiting as of available data [15].

Key Research Highlights:

• 96-week study duration assesses sustained post-surgical weight maintenance
• Adjuvant rather than standalone application distinguishes from other obesity trials
• Severe obesity population differs from standard trial populations
• Results anticipated to inform combination therapy strategies for high-BMI patients

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

Mazdutide is administered subcutaneously, bypassing first-pass hepatic metabolism that would degrade an orally administered peptide. Subcutaneous absorption is gradual, producing a flat concentration profile over several days rather than a sharp peak. Phase 1 pharmacokinetic data confirmed a half-life of approximately 8 days, supporting the once-weekly dosing regimen used across all clinical trials [4].

Moderate pharmacokinetic variability between subjects was noted in Phase 1 high-dose studies. Sources of variability include subcutaneous injection site, individual differences in albumin binding capacity, and body composition differences affecting subcutaneous depot volume and absorption kinetics.

Distribution and Metabolism

The fatty acid chain modification enables albumin binding in plasma. Albumin binding serves as a pharmacokinetic depot, slowly releasing free mazdutide for receptor engagement over time. This mechanism is shared with other fatty acid-conjugated peptides including GLP1-S.

Tissue distribution follows receptor expression patterns. GLP-1 receptors are expressed in pancreatic beta cells, the gastrointestinal tract, the central nervous system, the heart, and the kidneys. Glucagon receptors are expressed predominantly in the liver, kidneys, and adipose tissue. Mazdutide distribution to these tissues drives the organ-specific effects observed in clinical studies.

Standard peptide degradation pathways apply once the fatty acid chain separates from albumin. Proteolytic cleavage by circulating and tissue-based peptidases inactivates the peptide backbone. No unusual metabolic routes have been identified in published pharmacokinetic analyses.

Delivery Methods Under Investigation

• Subcutaneous injection (weekly): The standard administration route across all Phase 1 through Phase 3 trials; produces consistent pharmacokinetic profiles supporting once-weekly dosing
• Dose escalation protocols: All clinical trials used dose escalation (starting at lower doses, titrating upward) to manage gastrointestinal tolerability during the initial weeks of treatment

No oral or other non-injectable formulations have been reported in published mazdutide research. The peptide’s molecular weight and susceptibility to gastrointestinal degradation make non-injectable formulations a significant formulation challenge.

Excretion and Clearance

The extended 8-day half-life results primarily from reduced renal clearance secondary to albumin binding. Albumin-bound peptide is too large for glomerular filtration; only free peptide clears renally. As the fatty acid chain dissociates from albumin, renal clearance of the free peptide contributes to elimination.

Steady-state plasma concentrations are achieved after approximately 4-5 weeks of weekly dosing, consistent with the pharmacokinetic half-life. Clinical trial endpoints measured at Week 12 through Week 52 therefore reflect steady-state pharmacology rather than single-dose effects.

Research Limitations and Evidence Gaps

Current Research Gaps

Population Diversity

• The majority of Phase 2 and Phase 3 trial participants are Chinese adults
• Pharmacogenomic and pharmacokinetic differences between ethnic populations are well-documented for metabolic conditions and their treatments
• Direct extrapolation of efficacy and safety findings to non-Asian populations requires validation in ethnically diverse trial cohorts
• International Phase 3 data (outside China) is not yet available in published form

Long-Term Safety Data

• The longest completed trial is 52 weeks (GLORY-2)
• Long-term cardiovascular outcomes, pancreatic effects, thyroid effects, and cancer risk data are absent
• GLP-1 receptor agonists as a class have known associations with thyroid C-cell tumors in rodents; whether this extends to dual agonists in humans is unknown
• The 96-week SMART trial will provide the longest available dataset but results are pending

Cardiovascular Outcome Evidence

• No dedicated cardiovascular outcome trial has completed
• Cardiometabolic marker improvements (blood pressure, lipids) are documented, but translation to reduced cardiovascular events is unproven
• The FDA and EMA typically require cardiovascular outcome trial data before approving glucose-lowering agents for type 2 diabetes

Mechanistic Gaps

• Optimal GLP-1R to GCGR potency ratio for different indications remains undetermined
• Long-term effects on pancreatic beta-cell function and glucagon secretion under sustained dual receptor stimulation are not well characterized
• The neuroprotective preclinical findings in diabetic mouse models have no human clinical correlate

Regulatory Approval Status

• Mazdutide holds no regulatory approvals as of available data
• Phase 3 data has been presented at conferences but full peer-reviewed publications for DREAMS-2, GLORY-1, and GLORY-2 are pending
• Regulatory submissions have not been publicly announced

Areas Needing Further Investigation

• Ethnically diverse Phase 3 populations to validate findings beyond Chinese trial cohorts
• Cardiovascular outcome trial to assess hard endpoint benefit
• Long-term safety beyond 52 weeks, including pancreatic, thyroid, and oncologic surveillance
• Direct head-to-head comparison with GLP1-S (DREAMS-3 is ongoing but results unavailable)
• Pediatric pharmacokinetic and safety data beyond the single adolescent case report
• Mechanistic clarification of uric acid reduction pathways
• Post-bariatric surgery efficacy and safety from the SMART trial

Regulatory and Research Status

Current Classification

Regulatory Approval Status
Mazdutide holds no therapeutic approval in any jurisdiction as of the available evidence base. The compound is classified as an investigational new drug in China under Innovent Biologics’ development program and carries analogous investigational status internationally under ex-China rights. Phase 3 data presented at EASD 2024 represents the current frontier of the evidence base; regulatory submissions have not been confirmed in published sources.

FDA Status
The FDA has not approved mazdutide for any indication. Phase 3 data generated primarily in Chinese populations would require additional international validation to satisfy FDA approval standards for a general US population indication. No FDA Breakthrough Therapy designation, Fast Track designation, or similar regulatory pathway acceleration has been publicly announced for mazdutide.

WADA Status
Mazdutide is not specifically listed on the current WADA Prohibited List. However, WADA’s prohibition of peptide hormones, growth factors, related substances, and mimetics is broad. Athletes subject to anti-doping rules should not assume unscheduled compounds are permitted; the general class prohibition may encompass mazdutide. Athletes under anti-doping jurisdiction should seek specific guidance from their sport’s governing body before any research compound exposure.

International Perspective
Innovent Biologics has advanced the most extensive clinical program, focused on the Chinese regulatory pathway under the National Medical Products Administration (NMPA). Chinese regulatory approval, if pursued following Phase 3 data, would not constitute international approval. European Medicines Agency and other major regulatory bodies have not issued public statements regarding mazdutide review timelines.

Research Community Approach

Mazdutide research proceeds through institutional clinical trial infrastructure with full IRB and ethics committee oversight. The compound’s extensive clinical dataset — seven Phase 3 trials — represents a level of human research investment unusual for investigational peptides, distinguishing it from preclinical-only research compounds. Researchers working with mazdutide operate within clinical trial regulatory frameworks rather than laboratory research chemical frameworks.

Future Research Directions

The DREAMS-3 head-to-head trial against GLP1-S is the most consequential pending study. GLP1-S currently dominates the GLP-1 agonist market and represents the standard against which new entrants are measured. Superior efficacy versus GLP1-S in a well-powered Phase 3 trial would significantly strengthen mazdutide’s regulatory and commercial development case. Results from DREAMS-3 and the SMART bariatric surgery adjuvant trial are the primary near-term data milestones. Regulatory submissions in China and internationally are likely to follow positive Phase 3 package completion.

Key Research Findings

Phase 1 Dose Escalation: Body Weight Reduction

Research Focus: Safety, tolerability, and preliminary efficacy of escalating mazdutide doses in Chinese adults with overweight or obesity
Key Results: The 9 mg dose produced 11.7% mean body weight reduction at 12 weeks versus 1.8% with placebo (p=0.0002). No serious drug-related adverse events occurred. Common mild adverse events were nausea, diarrhea, and vomiting [9].
Significance: Established proof-of-concept for meaningful weight reduction and confirmed the once-weekly subcutaneous dosing schedule as feasible and tolerable.
Limitations: Short 12-week follow-up; single ethnic population; small Phase 1 sample sizes.

Phase 1 High-Dose Extension: Pharmacokinetic Confirmation and Metabolic Biomarkers

Research Focus: Safety, tolerability, and metabolic effects at doses up to 16 mg with pharmacokinetic characterization
Key Results: Approximately 8-day half-life confirmed, supporting weekly dosing. Greater weight loss at 16 mg than prior 10 mg trials. Reduced fasting glucose, fasting insulin, and HbA1c. Elevated beta-hydroxybutyrate confirmed active hepatic fatty acid oxidation. No increase in beta-cell stress markers [4].
Significance: Confirmed the glucagon receptor-mediated mechanism through direct biomarker evidence. Established that higher doses increase efficacy without activating insulin stress pathways.
Limitations: Small sample size; absence of comparator arm limits interpretation of magnitude.

Phase 2 Obesity Trial: Dose-Response Characterization

Research Focus: Dose-response relationship for body weight reduction in overweight and obese Chinese adults at 3, 4.5, and 6 mg weekly
Key Results: Mean body weight reductions of 6.7% (3 mg), 10.4% (4.5 mg), and 11.3% (6 mg) versus placebo gain of 1.0% at interim analysis. At 24 weeks with 6 mg, 50.8% of participants achieved at least 10% body weight loss versus 0% on placebo. Reductions in waist circumference, blood pressure, and lipids confirmed [10].
Significance: Established clear dose-response relationship and demonstrated that clinically meaningful weight loss (greater than 10%) is achievable in half of treated subjects.
Limitations: Chinese adult population; no active comparator arm; 24-week maximum follow-up.

DREAMS-2 Phase 3: Head-to-Head Superiority Over Dulaglutide

Research Focus: Comparison of mazdutide 4 mg and 6 mg weekly against dulaglutide 1.5 mg weekly in Chinese adults with type 2 diabetes on oral antidiabetic agents over 28 weeks
Key Results: Mazdutide demonstrated superior HbA1c reduction (0.25-0.30 percentage points greater), superior body weight loss, and superior composite endpoint achievement versus dulaglutide. Additional superiority on fasting glucose, postprandial glucose, waist circumference, blood pressure, lipids, uric acid, and ALT [13].
Significance: First Phase 3 head-to-head demonstration that dual GLP-1R/GCGR agonism produces measurably better outcomes than GLP-1R-selective therapy across multiple metabolic endpoints.
Limitations: Dulaglutide 1.5 mg is not the highest available dulaglutide dose; Chinese population only; peer-reviewed publication pending for full methodology and data.

GLORY-2 Phase 3: One-Year Weight Reduction in Non-Diabetic Obesity

Research Focus: Efficacy and safety of mazdutide 9 mg weekly over 52 weeks in obese Chinese adults without diabetes
Key Results: Primary endpoints met. Body weight reduction up to 20.1% at 52 weeks. Significant reductions in waist circumference, blood lipids, blood pressure, uric acid, liver enzymes, and hepatic fat content [11].
Significance: Establishes mazdutide among compounds achieving approximately 20% weight reduction over one year — a threshold that approaches outcomes historically associated with bariatric surgery.
Limitations: Chinese population only; single-arm efficacy comparison to placebo; no active comparator arm; peer-reviewed publication pending.

Adolescent Case Report: Pediatric Feasibility Signal

Research Focus: Observational case report of a 15-year-old male with obesity, type 2 diabetes, and hyperuricemia treated with dose-escalated mazdutide plus standard therapy
Key Results: Improved HbA1c from 9.60% baseline, reduced BMI by 8.78-10.99%, reduced uric acid, reversed hepatic steatosis, improved lipid profile. No hypoglycemia or hypotension episodes. Complete protocol adherence [14].
Significance: Provides a preliminary signal that mazdutide’s mechanisms remain active in adolescent physiology and that the compound may be relevant to pediatric metabolic disease research.
Limitations: Single case report; no control; cannot establish causality or generalizability; pediatric-specific pharmacokinetic data absent.

Meta-Analysis: Safety Across the Mazdutide Clinical Program

Research Focus: Aggregated safety analysis across mazdutide clinical trials in mixed diabetic and non-diabetic adult populations
Key Results: Favorable overall safety profile. Mazdutide does not increase hypoglycemia risk as monotherapy or in combination. Gastrointestinal adverse events elevated versus placebo: nausea risk ratio 4.22 vs. placebo; diarrhea, decreased appetite, vomiting, and abdominal distension also elevated [16].
Significance: Confirms the GI tolerability challenge consistent with the GLP-1 class while establishing that hypoglycemia risk does not compound with dual receptor agonism.
Limitations: Meta-analyses of heterogeneous trials have inherent methodology limitations; publication bias toward positive results affects pooled safety estimates.

Frequently Asked Questions

What is mazdutide and how is it different from other weight loss drugs?

Mazdutide is a research peptide that activates two receptors involved in metabolism — the GLP-1 receptor and the glucagon receptor — simultaneously. Most current weight loss drugs in this category, like GLP1-S, only activate the GLP-1 receptor. Mazdutide’s additional glucagon receptor activity increases fat burning and energy expenditure on top of the appetite suppression that GLP-1-only drugs provide, which is why clinical trials show larger weight reductions compared to single-target agents.

What kind of weight loss has been seen in mazdutide research?

Clinical trials have shown body weight reductions ranging from about 11% at 12 weeks in early Phase 1 studies to up to 20.1% at one year in the GLORY-2 Phase 3 trial in obese adults. For context, achieving 20% body weight reduction is a threshold that has historically been associated with bariatric surgery rather than medication. These results come from controlled research trials and represent findings in specific study populations, not predictions for any individual.

Has mazdutide been studied in people with type 2 diabetes?

Yes. Multiple Phase 2 and Phase 3 trials have investigated mazdutide in adults with type 2 diabetes. The DREAMS-2 Phase 3 trial compared mazdutide directly to dulaglutide (a widely used GLP-1 medication) and found mazdutide produced superior reductions in HbA1c, body weight, blood pressure, lipids, and several other metabolic markers. Phase 2 studies showed HbA1c reductions of 1.41% to 1.67% at 20 weeks, which is clinically meaningful in diabetes management research.

Is mazdutide approved for use?

No. Mazdutide is an investigational compound with no regulatory approval in any country as of available data. It has completed multiple Phase 3 clinical trials with results presented at the EASD 2024 conference, but full peer-reviewed publications for the major Phase 3 trials are still pending, and no regulatory submission timeline has been publicly announced. The compound is classified as a research-only compound.

What side effects have been observed in mazdutide research?

The most commonly reported adverse events in mazdutide clinical trials are gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, and abdominal distension. These are consistent with the GLP-1 receptor agonist class of compounds. They are predominantly mild to moderate in severity and tend to diminish with continued dosing. All trials used dose escalation schedules to manage initial gastrointestinal tolerability. Hypoglycemia rates were low and not significantly elevated above placebo rates in trials not combining mazdutide with insulin or sulfonylureas.

References

1. Drucker, D.J. (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism, 57, 101351. PubMed

2. Secher, A., et al. (2014). The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation, 124(10), 4473-4488. PubMed

3. Nauck, M.A., & Meier, J.J. (2018). Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism, 20(S1), 5-21. PubMed

4. Yan, J., et al. (2024). Safety, tolerability, pharmacokinetics, and pharmacodynamics of mazdutide (IBI362/LY3305677) at up to 16 mg in adults with overweight or obesity. Diabetes, Obesity and Metabolism, 26(9), 3785-3795. PubMed

5. Loomba, R., et al. (2023). Glucagon receptor agonism in non-alcoholic fatty liver disease: Mechanisms and clinical implications. Journal of Hepatology, 78(2), 425-437. PubMed

6. Salem, V., et al. (2014). Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. Diabetes, Obesity and Metabolism, 16(1), 72-77. PubMed

7. Pocai, A., et al. (2009). Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes, 58(10), 2258-2266. PubMed

8. Zhu, M., et al. (2023). Mazdutide improves cognitive function and neuronal integrity in diabetic mouse models beyond the effects of GLP-1 receptor agonism. Frontiers in Neuroscience, 17, 1127386. PubMed

9. Liu, J., et al. (2023). Efficacy and safety of mazdutide in Chinese adults with overweight or obesity: A randomized, double-blind, placebo-controlled Phase 1 study. Obesity, 31(4), 955-965. PubMed

10. Ji, L., et al. (2023). Dose-response efficacy and safety of mazdutide in overweight and obese Chinese adults: A Phase 2 randomized controlled trial. eClinicalMedicine, 61, 102063. PubMed

11. Innovent Biologics. (2024). GLORY-2 Phase 3 trial: Mazdutide 9 mg achieves up to 20.1% body weight reduction at 52 weeks in obese Chinese adults. Presented at EASD Annual Meeting 2024, Madrid, Spain.

12. Cai, X., et al. (2023). Mazdutide reduces HbA1c and body weight in Chinese adults with type 2 diabetes: Phase 2 trial results. Diabetes Care, 46(6), 1220-1228. PubMed

13. Innovent Biologics. (2024). DREAMS-2 Phase 3 trial: Mazdutide demonstrates superior HbA1c reduction and weight loss versus dulaglutide in type 2 diabetes. Presented at EASD Annual Meeting 2024, Madrid, Spain.

14. Chen, Y., et al. (2024). Mazdutide treatment in a 15-year-old male with obesity, type 2 diabetes, and hyperuricemia: A case report. Frontiers in Endocrinology, 15, 1380215. PubMed

15. ClinicalTrials.gov. (2024). SMART trial: Mazdutide as adjuvant therapy post-sleeve gastrectomy in severe obesity (NCT07135141). U.S. National Library of Medicine.

16. Wang, Y., et al. (2024). Efficacy and safety of mazdutide in adults with overweight, obesity, and type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 26(11), 5120-5132. PubMed

17. Day, J.W., et al. (2012). A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nature Chemical Biology, 5(10), 749-757. PubMed

18. Finan, B., et al. (2015). Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Science Translational Medicine, 7(313), 313ra182. PubMed

19. Tan, T.M., et al. (2013). Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes, 62(4), 1131-1138. PubMed

20. Friedrichsen, M., et al. (2021). The effect of glucagon-like peptide 2 on glucose metabolism in healthy men: A randomized crossover study. American Journal of Physiology, Endocrinology and Metabolism, 321(1), E34-E43. PubMed